%0 Journal Article
%A Renovanz, Mirjam
%A Kurz, Sylvia C
%A Rieger, Johannes
%A Walter, Bianca
%A Becker, Hannes
%A Hille, Hanni
%A Bombach, Paula
%A Rieger, David
%A Grosse, Lucia
%A Häusser, Lara
%A Skardelly, Marco
%A Merk, Daniel J
%A Paulsen, Frank
%A Hoffmann, Elgin
%A Gani, Cihan
%A Neumann, Manuela
%A Beschorner, Rudi
%A Rieß, Olaf
%A Roggia, Cristiana
%A Schroeder, Christopher
%A Ossowski, Stephan
%A Armeanu-Ebinger, Sorin
%A Gschwind, Axel
%A Biskup, Saskia
%A Schulze, Martin
%A Fend, Falko
%A Singer, Stephan
%A Zender, Lars
%A Lengerke, Claudia
%A Brucker, Sara Yvonne
%A Engler, Tobias
%A Forschner, Andrea
%A Stenzl, Arnulf
%A Kohlbacher, Oliver
%A Nahnsen, Sven
%A Gabernet, Gisela
%A Fillinger, Sven
%A Bender, Benjamin
%A Ernemann, Ulrike
%A Öner, Öznur
%A Beha, Janina
%A Malek, Holly Sundberg
%A Möller, Yvonne
%A Ruhm, Kristina
%A Tatagiba, Marcos
%A Schittenhelm, Jens
%A Bitzer, Michael
%A Malek, Nisar
%A Zips, Daniel
%A Tabatabai, Ghazaleh
%T Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
%J Neuro-oncology advances
%V 5
%N 1
%@ 2632-2498
%C Oxford
%I Oxford University Press
%M DKFZ-2023-00528
%P 1-14
%D 2023
%X The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular profiling and targeted therapy in adult patients with advanced tumors in the nervous system within a prospective observational study.molecular tumor board (MTB)@ZPM (NCT03503149) is a prospective observational precision medicine study for patients with advanced tumors. After inclusion of patients, we performed comprehensive molecular profiling, formulated ranked biomarker-guided therapy recommendations based on consensus by the MTB, and collected prospective clinical outcome data.Here, we present initial data of 661 adult patients with tumors of the nervous system enrolled by December 31, 2021. Of these, 408 patients were presented at the MTB. Molecular-instructed therapy recommendations could be made in 380/408 (93.1
%K MTB@ZPM-001 (NCT03503149) (Other)
%K Molecular tumor board (Other)
%K precision medicine (Other)
%K real-world data (Other)
%K targeted therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36915613
%2 pmc:PMC10007909
%R 10.1093/noajnl/vdad012
%U https://inrepo02.dkfz.de/record/274242